Plus: dasiglucagon; metformin abandonment; more
Saturday, Aug. 7, 2021 : Issue #1156 TOP STORIES - Diabetes News & Research |
|
Letter from the Editor
There has been a lot of clamor over the introduction of Wegovy for weight loss. The GLP-1 mimetic had such a huge introduction that supply was not able to keep up with demand. This is a double strength Ozempic product and looks to help patients with obesity as well as diabetes patients. Does this mean that if we double the dose of drugs like the SGLT-2 inhibitors, we will get extra weight loss as well?
It is likely those studies are going on right now as our intern Kornelia Ilias, Pharm.D. Candidate, Creighton University School of Pharmacy, found some new evidence that in certain populations the SGLT-2 inhibitors cause more weight loss than the GLP-1 mimetics. Click on her Laterpay article to find out who these drugs worked best for.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief |
|
| |
|
|
|
TOP STORIES - Diabetes News and Research |
|
| |
|
|
|
| Fact: Half Abandon Metformin Within a Year of Diagnosis
New data shows that nearly half of adults prescribed metformin after a new diagnosis of T2D stopped taking their metformin within one year.
From a retrospective analysis of administrative data, the findings from 2012-2017 also show that the fall-off in metformin adherence was most dramatic during the first 30 days. In most cases, there was no concomitant substitution of another glucose-lowering drug.
One of the reasons for the discontinuation is that patients might not realize the importance of taking the medication; that is where the education comes in. If the patient understood why they are taking the medications and what the medication is doing to reduce their risk for the complications, they would not stop. So often, the physician writes the prescription for 3 months and refills for a year, yet no one monitors whether the patient continues to fill the prescription.
Side effects are an issue, but not for most. Any clinician who prescribes metformin knows side effects, such as upset stomach, diarrhea, and nausea. But certainly, it's not half [who experience these]…. Many people don't accept taking it lifelong, especially since they probably don't feel any better about it. Communication with the patient is key to preventing the discontinuation of their medications.
The data were recently published online in Diabetic Medicine by David J. T. Campbell, MD, Ph.D., of the University of Calgary, Alberta, Canada, and colleagues. |
|
|
| Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters: Macrina Ghali, PharmD Candidate 2021, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences Kornelia Ilias, Creighton University | School of Pharmacy and Health Professions Doctor of Pharmacy Candidate Class of 2022 Alan Martinez, PharmD Candidate, University of South Florida Taneja College of Pharmacy |
|
|
|
|
|
| | About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control. |
| Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com |
|
|
|
|
| | |
|
|
|
|
